GlassScriptPhysician profile
Deepak Mittal
NPI 1447296538
$5,130.02
in general payments reported to CMS, 2019-2025
29 companies · $1,490 in 2025
The $1,490 reported for 2025 was more than what 86% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $83.55 · 2021: $291 · 2022: $1,171 · 2023: $1,037 · 2024: $951 · 2025: $1,490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Education: $97.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.98 |
| Education | $97.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,301.92 | 2020-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $538.09 | 2020-2025 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $434.21 | 2022-2025 | Tarpeyo |
| Amgen INC. | $416.60 | 2019-2025 | Krystexxa, Tavneos, Repatha |
| Otsuka America Pharmaceutical, INC. | $365.98 | 2022-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $312.25 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Bayer Healthcare Pharmaceuticals INC. | $292.68 | 2021-2025 | |
| Travere Therapeutics, INC. | $227.95 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $209.85 | 2022-2025 | |
| Novo Nordisk INC | $134.82 | 2023-2025 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.70 | 2024-2025 | Jardiance |
| Ardelyx, INC. | $97.42 | 2024-2025 | Ibsrela |
| Aurinia Pharma U.S., INC. | $92.19 | 2023-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $88.02 | 2021-2022 | |
| Daiichi Sankyo INC. | $73.47 | 2022-2025 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $62.37 | 2019-2023 | Ultomiris |
| Shield Therapeutics INC | $53.95 | 2025 | |
| Akebia Therapeutics INC | $40.81 | 2022 | |
| Lilly USA, LLC | $38.77 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $36.97 | 2024-2025 | Rayaldee |
| Glaxosmithkline, LLC. | $36.69 | 2023-2025 | Benlysta, Shingrix, Arexvy |
| Horizon Therapeutics Plc | $30.51 | 2022-2023 | Krystexxa |
| Alnylam Pharmaceuticals INC. | $25.41 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.30 | 2024 | Crysvita |
| Quanta Dialysis Technologies INC | $22.07 | 2021 | |
| Apellis Pharmaceuticals, INC. | $21.88 | 2025 | Empaveli |
| Takeda Pharmaceuticals U.S.A., INC. | $19.21 | 2022 | |
| Abiomed | $16.78 | 2024 | Impella |
| Ani Pharmaceuticals, INC. | $12.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deepak Mittal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.